Table 1.
Monoclonal antibodies and antibody-drug conjugates in development for MM
| Target | Agent | Type (toxin) | Comments | Clinical trials no.* |
|---|---|---|---|---|
| SLAMF7 | Elotuzumab | Naked | FDA approved | Multiple |
| CD38 | Daratumumab | Naked | FDA approved | Multiple |
| CD38 | Isatuximab | Naked | Phase 3 combo with pom/dex under FDA review | NCT02990338 |
| CD38 | MOR202 | Naked | Combinations with dex, len/dex, and pom/dex | NCT01421186 |
| CD38 | TAK-079 | Naked | Subcutaneous administration, phase 1 single agent | NCT03439280 |
| CD38 | TAK-573 | ADC (IFNα) | Phase 1 single agent | NCT03215030 |
| CD38 | TAK-169 | ADC (shiga-like toxin A subunit) | Preclinical | |
| BCMA | SEA-BCMA | Naked | Phase 1 single agent | NCT03582033 |
| BCMA | GSK2857916 (belantamab mafodotin) | ADC (MMAF) | 21 of 35 (60%) ORR in phase 1 expansion; ongoing trials alone and with len/dex, pom/dex, bort/dex, pembrolizumab | NCT02064387, NCT03525678, NCT03544281, NCT03848845, NCT03715478 |
| BCMA | MEDI2228 | ADC (PBD) | Phase 1 single agent | NCT03489525 |
| BCMA | HDP-101 | ADC (Amanitin) | Preclinical | |
| CD48 | SGN48A | ADC (MMAE) | Phase 1 single agent | NCT03379584 |
| CD46 | FOR46 | ADC (MMAF) | Phase 1 single agent | NCT03650491 |
| CD56 | IMGN901 (lorvotuzumab mertansine) | ADC (DM1) | 2 of 37 (6%) ORR in phase 1 | NCT00346255 |
| CD74 | STRO-001 | ADC (SC236) | Phase 1 single agent | NCT03424603 |
ADC, antibody-drug conjugate; bort, bortezomib; dex, dexamethasone; DM1, maytansinoid; IFNα, interferon-α; len, lenalidomide; MMAE, monomethyl auristatin E; MMAF, monomethyl auristatin F; ORR, overall response rate (partial response or better); PBD, pyrrolobenzodiazepine; pom, pomalidomide; SC236, noncleavable maytansinoid-linker warhead.
*
Search conducted on www.clinicaltials.gov on May 15, 2019.